At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 57 enrolled
Drug / intervention
Ziprasidonedrug
Likely dose
Ziprasidone 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder
In Brief
A Phase 3 clinical trial evaluating Ziprasidone for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 57 participants across 1 site.
Detailed Summary
The aim of the protocol is to study the effects of 320 mg/day of ziprasidone (Geodon) on glucose and lipid metabolism of patients with both Diabetes Type II (DM) and schizophrenia or schizoaffective disorder, after switching their antipsychotic medication/s from typical and/or atypical to ziprasidone monotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2003
First PostedNov 2006
Primary CompletionJan 2010
TodayJul 2026
First PostedNov 2, 2006
Enrollment StartSep 1, 2003
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 19.7 years ago
Interventions
Ziprasidonedrug
Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks